Vindhya Vasini Andra

Abstract Agentic systems are proposed for clinical decision support, yet unrestricted tool access can undermine accountability and safety in precision oncology, where recommendations must be grounded in evolving guidelines, regulatory labels, and patient-specific molecular evidence.

Abstract : Cancer treatments with targeted therapy have gained immense interest due to their low levels of toxicity and high selectivity. Proteolysis-Targeting Chimeras (PROTACs) have drawn special attention in the development of cancer therapeutics owing to their unique mechanism of action, their ability to target undruggable proteins, and their focused target engagement.